Publicaciones científicas

Interaction of glucocorticoids with FXR/FGF19/FGF21-mediated ileum-liver crosstalk

01-sep-2018 | Revista: Biochimica et Biophysica Acta - Molecular Basis of Disease

Faten A Al-Aqil, Maria J Monte, Ana Peleteiro-Vigil, Oscar Briz, Ruben Rosales, Raquel González, Carlos J Aranda, Borja Ocón, Iker Uriarte, Fermín Sánchez de Medina, Olga Martinez-Augustín, Matías A Avila, José J G Marín, Marta R Romero


At high doses, glucocorticoids (GC) have been associated with enhanced serum bile acids and liver injury. We have evaluated the effect of GC, in the absence of hepatotoxicity, on FXR/FGF91(Fgf15)/FGF21-mediated ileum-liver crosstalk. Rats and mice (wild type and Fxr-/-, Fgf15-/- and int-Gr-/- strains; the latter with GC receptor (Gr) knockout selective for intestinal epithelial cells), were treated (i.p.) with dexamethasone, prednisolone or budesonide. In both species, high doses of GC caused hepatotoxicity.

At a non-hepatotoxic dose, GC induced ileal Fgf15 down-regulation and liver Fgf21 up-regulation, without affecting Fxr expression. Fgf21 mRNA levels correlated with those of several genes involved in glucose and bile acid metabolism. Surprisingly, liver Cyp7a1 was not up-regulated. The expression of factors involved in transcriptional modulation by Fxr and Gr (p300, Drip205, CBP and Smrt) was not affected. Pxr target genes Cyp3a11 and Mrp2 were not up-regulated in liver or intestine.

In contrast, the expression of some Pparα target genes in liver (Fgf21, Cyp4a14 and Vanin-1) and intestine (Vanin-1 and Cyp3a11) was altered. In mice with experimental colitis, liver Fgf21 was up-regulated (4.4-fold). HepG2 cells transfection with FGF21 inhibited CYP7A1 promoter (prCYP7A1-Luc2). This was mimicked by pure human FGF21 protein or culture in medium previously conditioned by cells over-expressing FGF21. This response was not abolished by deletion of a putative response element for phosphorylated FGF21 effectors present in prCYP7A1.

In conclusion, GC interfere with FXR/FGF19-mediated intestinal control of CYP7A1 expression by the liver and stimulate hepatic secretion of FGF21, which inhibits CYP7A1 promoter through an autocrine mechanism.

CITA DEL ARTÍCULO  Biochim Biophys Acta Mol Basis Dis. 2018 Sep;1864(9 Pt B):2927-2937. doi: 10.1016/j.bbadis.2018.06.003. Epub 2018 Jun 6.

Nuestros autores

Iker Uriarte Díaz-Varela
Investigador Adscrito a Proyecto Programa de Investigación de Hepatología